Comparing two drug combos before surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer that has not spread to distant organs.
- You have not had surgery, chemotherapy, or targeted therapy for this breast cancer before.
- You are 18 years or older and in generally good health (able to do daily activities).
- Your kidney, liver, and heart function are within certain safe limits.
- You have not had significant nerve damage from other causes.
- You are willing to have a small piece of your stored tumor tissue sent for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drugs, trastuzumab rezetecan and trastuzumab deruxtecan, given before surgery to shrink HER2-positive breast cancer tumors. It aims to see which drug works better and has fewer side effects, potentially offering a more effective treatment option for patients.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.